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Abstract 
[68Ga]Ga-DOTA-NOC was produced under an Expanded Access IND for 174 clinical 
PET/CT studies to evaluate patients with neuroendocrine tumors. Production employed 
either the TiO2-based Eckert & Ziegler (EZAG) 68Ge/68Ga-generator (with fractionated 
elution), or the SiO2-based ITG 68Ge/68Ga-generator. In both cases, [68Ga]Ga-DOTA-
NOC was reliably produced, without pre-synthesis purification of the 68Ga generator 
eluate, using readily-implemented manual synthesis procedures. [68Ga]Ga-DOTA-NOC 
radiochemical purity averaged 99.2 ± 0.4%. Administered 68Ga dose averaged 181 ± 22 
MBq, and administered peptide mass averaged 43.2 ± 5.2 µg (n = 47) and 23.9 ± 5.7 µg 
(n = 127), respectively, using the EZAG and ITG generators. At dose expiration, 68Ge 
breakthrough in the final product averaged 2.7 x 10-7% and 5.4 x 10-5 % using the EZAG 
and ITG generators, respectively.  
 
 
Introduction 
 
Gallium-68-labeled somatostatin-receptor-targeted peptides, such as  [68Ga]Ga-DOTA-
NOC, [68Ga]Ga-DOTA-TOC, and [68Ga]Ga-DOTA-TATE, have found widespread clinical 
use in Europe for positron emission tomography (PET) detection of neuroendocrine 
tumors (Virgolini, et al., 2010; Pettinato, et al., 2008; Prasad and Baum, 2010; Prasad, et 
al., 2010; Ambrosini, 2010), but none are FDA-approved drug products in the USA. 
These three targeting peptides vary slightly in amino acid sequence, resulting in 
variations in their receptor affinities and receptor-sub-type selectivity (Antunes, et al., 
2007 ), but all appear suitable for use in clinical imaging (Virgolini, et al., 2010).  
 
The Expanded Access IND (Investigational New Drug exemption) can be a mechanism 
for providing patient access to a drug product that is not FDA-approved, but that is 
clinically needed in treatment of a serious disease (21CFR312.305, 2013). In response 
to a local clinical need to better define the location and extent of disease in 
neuroendocrine cancer patients who are candidates for multivisceral transplant (Mangus 
, el al., 2013), a manual synthesis method was developed for on-demand preparation of 
the [68Ga]Ga-DOTA-NOC peptide-chelate conjugate in a formulation suitable for 
intravenous administration, and an Expanded Access IND submitted to the FDA 
documenting the production procedure and the intended clinical use. We selected 
[68Ga]Ga-DOTA-NOC because our clinical focus was to define extent of disease, and 
this agent offers affinity for a broader range of receptor sub-types than [68Ga]Ga-DOTA-
TOC or [68Ga]Ga-DOTA-TATE ([68Ga]Ga-DOTA-NOC exhibits significant affinity for 
ssrt3, sstr4, sstr5, as well as the sstr2 receptor sub-type most commonly expressed by 
neuroendocrine tumors) (Atunes, et al., 2007).  
 
We describe here our experience with manual radiochemical synthesis of [68Ga]Ga-
DOTA-NOC for clinical use under Expanded Access IND 117,255.  The manual 
approach to synthesis was chosen because of the expected limited production volume, 
and the desire for a simple process that could be rapidly implemented and validated with 
minimal expense, since start-up and dose production costs needed to be recovered by 
charges to the patient. 
MATERIALS and METHODS 
 
As required for an Expanded Access IND by the U.S. Food and Drug Administration 
(FDA), our clinical use of [68Ga]Ga-DOTA-NOC in clinical PET/CT imaging was reviewed 
and approved by an Indiana University Institutional Review Board (IRB). All patients 
provided written informed consent prior to administration of the [68Ga]Ga-DOTA-NOC 
radiopharmaceutical. Clinical imaging was generally performed as an outpatient 
procedure using a Siemens mCT extended FOV time-of-flight PET/CT (128 slice) 
camera, with a few in-patient studies instead performed using a Siemens Biograph-64 
PET/CT. Whole-body (head to mid-thigh) PET acquisitions were started at 60-minutes 
post-injection with data collection occurring over a period of ~24-minutes. 
 
The DOTA-NOC peptide conjugate was purchased from ABX GmbH as commercial 
cGMP-grade product packaged at 60-µg per vial.  Two TiO2-based Eckert & Ziegler 
(EZAG) IGG100 68Ge/68Ga generators (50-mCi; 1.85 GBq), and four SiO2-based ITG 
Isotope Technologies Garching GmbH 68Ge/68Ga generators (30-mCi; 1.11 GBq), have 
been employed to supply 68Ga for manual synthesis of [68Ga]Ga-DOTA-NOC under 
Expanded Access IND #117,255. While not specified by the generator manufacturers, in 
both cases we filtered the aqueous HCl generator eluent through an HCl-stable 25-mm 
sterile 0.2-µm filter (Supor® polyethersulfone membrane in acrylic housing, part 
#H938210023, Baxa, Englewood, CO) attached to the generator inlet. To minimize 
introduction of trace metal impurites that would compete with 68Ga3+ for binding the 
DOTA-NOC chelator, generator eluate was prepared by dilution of ultrapure 
concentrated HCl (HCl 30%, Suprapur®, EM Science, Gibbstown, NJ) with ultrapure 
water (NERL®, Thermo Scientific, Middletown, VA). Reaction mixture buffering employed 
only ultrapure sodium acetate (99.999%; Atomergic Chemetals Corporation, 
Farmingdale, NY) in a 0.25M solution prepared using ultrapure water. 
 
Synthesis of the [68Ga]Ga-DOTA-NOC radiopharmaceutical employed no-carrier-added 
68Ga3+ in either 1.5 mL 0.1M ultrapure HCl (fractionated elution of the EZAG generator), 
or 4.0-mL 0.05M ultrapure HCl (ITG generator, without fractionation). The eluate was 
buffered to pH ~4.8 by addition of ultrapure NaOAc and reacted with the DOTA-NOC 
conjugate (60-µg for the EZAG eluate; 30-µg for the ITG eluate) with heating for 10-
minutes.  For our initial manual synthesis method, the reaction mixture was heated in a 
sterile 15-mL polypropylene centrifuge tube using an Eppendorf Thermomixer (Figure 1) 
set at 80°C.  Using the ITG generator we initially employed this same synthetic method, 
but then adapted our process to employ ITG’s manually controlled Fluidic Module (Vis, 
et al., 2015; Tworowska et al., 2016; Roesch, 2012) for better radiation shielding during 
solution transfers.  Required solution transfers in our process using the EZAG generator 
were simply made using syringes and needles (4-inch B Braun Medication Transfer 
Filter Straws and 3.5-inch 18-gauge spinal needles), employing tungsten syringe shields 
to minimize hand exposure. The ITG Fluidic Module (Vis, et al., 2015; Tworowska et al., 
2016; Roesch, 2012) employs a single-use assembly of a reaction vessel that is 
plumbed with sterile medical tubing and Luer adapters, connectors, and valves; the 
radiochemical synthesis can then proceed in a compact shielded bench-top unit using 
external syringes for reagent additions and transfers, with the operator manually 
controlling fluid pathways via external knobs for changing the positions of the enclosed 
3-way and 2-way valves. Following ITG’s recommended protocol, the thermostat for the 
Fluidic Module heating element was set to 105°C, resulting in a reactor solution 
temperature of 90-100°C. 
 
The [68Ga]Ga-DOTA-NOC product was always isolated by C18 solid-phase extraction 
(Waters C18 SepPak® Light), and then washed by passage of 5-10 mL of either sterile 
water or sodium chloride for injection. (Prior to use, the C18 solid phase extraction 
cartridge was conditioned by flushing with 5-10 mL absolute ethanol USP, followed by 
10-mL sterile water for injection.) To reliably maintain trapping efficiency for the 
[68Ga]Ga-DOTA-NOC product, loading to the C18 solid-phase extraction cartridge 
needed to occur very slowly (i.e., with drop-wise flow at the outlet) if the reaction mixture 
was transferred without prior cooling. 
 
The [68Ga]Ga-DOTA-NOC was then recovered by elution of the C18 SepPak® with 
ethanol:saline (0.6-mL, 85:15; or 1.0-mL, 50:50), collecting the intermediate product in a 
sterile polypropylene centrifuge tube where it was diluted to ≤5% ethanol with either 12-
mL or 10-mL sterile saline. The [68Ga]Ga-DOTA-NOC intermediate product solution was 
then drawn into a shielded sterile syringe for terminal sterilizing filtration (13-mm 0.2-µm 
PVDF filter, WhatmanTM 6791-1302, GE Healthcare Life Sciences) within a laminar flow 
hood into a sterile evacuated vial (30-mL, vial #7521ZA, Jubilant HollisterStier, Spokane, 
WA; Figure 2). Since the [68Ga]Ga-DOTA-NOC  radiopharmaceutical was always being 
prepared for immediate use, the dose expiration time was set as 60-minutes after the 
sterilizing filtration to yield final product. 
 
Pre-release product quality control procedures included: half-life measurement for 
confirmation of radionuclidic identity; pH measurement; ITLC assessment of 
radiochemical purity; endotoxin testing (Endosafe®-PTS, Charles River Laboratories); 
and a bubble point measurement to confirm the integrity of the single-use sterile 0.2-µm 
filter employed for terminal product sterilization. The half-life determination was made 
using a radionuclide dose calibrator (Capintec CRC-55tW) to make eight timed 
measurements of 68Ga radioactivity over a 7-minute period, calculating the 
corresponding half-life from the slope of the regression line in a spreadsheet plot of 
ln(radioactivity) vs. time (Apple iPad® running Numbers® application). The measured 
half-life was required to fall in the range of 64.6 - 71.4 minutes. The ITLC determination 
of radiochemical purity employed ITLC-SG strips developed with 0.1M HCl to quantify 
levels of ionic 68Ga, and ITLC-SG strips developed with 1:1 MeOH:1M NH4OAc to 
quantify colloidal 68Ga-hydroxide plus ionic 68Ga (Gallium Edotreotide Injection, 2010). In 
process validation, the ITLC strips were analyzed with a Bioscan AR-2000 
radiochromatogram scanner fitted with high-resolution collimator (Figure 3). But, for 
speed and simplicity, our routine quality control instead employed a NaI(Tl) well 
scintillation counter to quantify radioactivity levels on the sectioned ITLC strip. For 
gamma counting, the ITLC-SG strip developed with 0.1M HCl was cut at the mid-point 
between the origin and solvent front, while the strip developed with 1:1 MeOH:1M 
NH4OAc was cut for counting at one-third the distance from the origin to the solvent 
front. 
 
Retrospective analysis of each production batch included sterility testing, and 
measurement of 68Ge breakthrough. Breakthrough was measured by NaI(Tl) scintillation 
counting of [68Ga]Ga-DOTA-NOC dose samples at both 15-20 hours, and 48-96 hours, 
after dose preparation, thereby quantifying original 68Ga, and breakthrough 68Ge/68Ga, 
respectively. (Beckman Gamma 8000 automatic gamma counter with 3-inch large-bore 
NaI(Tl) crystal. Counting window centered at 511 keV.  60-minute counting periods were 
employed for the final assay, since at the lowest observed breakthrough levels the 
sample count rates were at, or near, the background count rate.) 
 
A more detailed description of the production processes employed with the EZAG and 
ITG generators, including SOPs and Batch Record documentation, is provided in the on-
line Supplementary Material. 
 
RESULTS AND DISCUSSION  
 
Our objective was to reliably produce the [68Ga]Ga-DOTA-NOC radiopharmaceutical for 
clinical use in accordance with the EANNMI procedure guidelines (Virgolini, et al., 2010), 
while minimizing both start-up and recurring costs. While automated synthesis systems 
are commercially available for peptide labeling with 68Ga, given the simplicity and scale 
of the required chemistry, our objectives were most effectively accomplished with the 
manual synthesis procedures described above.  
 
The elution profile of the EZAG and ITG generators are similar, with nearly all the 
available 68Ga delivered in ≤2 mL of the total 4-5 mL elution volume. We employed 
fractionated elution of the EZAG generator system to minimize introduction of trace 
metals into the [68Ga]Ga-DOTA-NOC reaction mixture, allowing labeling with consistently 
high yields while avoiding pre-synthesis clean-up of the generator eluate (Di Pierro, et 
al., 2008; Schultz, et al., 2013; Eppard, et al., 2014)]. Specifically, after discarding the 
generator void volume, we collected the next ~1.8-mL of EZAG generator eluate for 
synthesis, transferring 1.5-mL of that volume to the reaction mixture, and using the 
remainder for the regulatory-mandated half-life measurement (performed during the 
synthesis heating period), plus a subsequent measure of the level of 68Ge breakthrough 
that was present in the reaction mixture. The generator void volume always proved 
stable over the 12-month period of generator use; however, void volume did vary slightly 
from generator-to-generator, making it critical to establish elution profile as part of the 
initial generator set-up testing if one expects to employ fractionated elution.  
 
Since it does not employ a metal oxide stationary phase, the ITG generator provides an 
eluate with very low contamination by trace metals (Vis, et al., 2015; Tworowska et al., 
2016; Roesch, 2012).  After pilot syntheses, we did not fractionate the ITG generator 
eluate, because we were able to obtain reliable product synthesis using the full 4-mL 
elution volume even employing a lower mass of the DOTA-peptide conjugate than used 
with the fractionated EZAG generator eluate (30-µg vs. 60-µg DOTA-NOC). In the case 
of product prepared with the ITG generator, the required half-life measurement was 
made using the final patient dose while awaiting completion of the endotoxin test.  
 
The ITG Fluidic Module is designed to minimize worker hand exposure, while enabling 
efficient manual performance of the steps required in radiopharmaceutical synthesis 
(Vis, et al., 2015; Tworowska et al., 2016; Roesch, 2012). ITG’s detailed operating 
procedure concludes with delivery of the 68Ga-DOTA-peptide into a final product vial via 
in-line sterilizing filtration. However, to minimize revisions to the IND production protocol 
we had already established using the EZAG generator, upon switching to the ITG 
generator we continued to process the ethanol:saline eluate from solid-phase-extraction 
(i.e., the [68Ga]Ga-DOTA-NOC intermediate product) without modification to our prior 
procedure. Thus, the ITG Fluidic Module was simply employed to remotely effect 
addition of reagents and generator eluate to the heated reaction vessel, and subsequent 
product loading to, and recovery from, the C18 SepPak® cartridge. Thus, as 
implemented, our protocol always applied the terminal sterilizing filtration (Figure 2) to 
the fully formulated [68Ga]Ga-DOTA-NOC product in 5% ethanol:saline. 
 
Table 1 summarizes our radiopharmaceutical production experience for the 174 patient 
doses of [68Ga]Ga-DOTA-NOC prepared in the first 3-years of Physician-Sponsored 
Expanded Access IND #117,255.  Two Eckert & Ziegler (EZAG) and four ITG 68Ge/68Ga 
generators were employed in this period.  Generator elution yields were higher with the 
ITG generator than the EZAG generator; and in both cases the elution yields were 
consistent with the manufacturer’s specifications. The radiochemical purity of the 
[68Ga]Ga-DOTA-NOC  product was consistently high, averaging 99.2 ± 0.4%  (Table 1), 
and never approached our 92% lower limit. All doses passed retrospective 14-day USP 
sterility testing, and had endotoxin levels at <5 EU/mL. The quantity of DOTA-NOC in 
the administered doses (Table 1) was always in keeping with the European Association 
of Nuclear Medicine Procedure Guidelines recommendation of ≤50 µg (Virgolini, et al., 
2010).  
 
68Ge breakthrough in the [68Ga]Ga-DOTA-NOC radiopharmaceutical (Table 1) was 
always far below the very conservative 0.001% upper limit (Virgolini, et al., 2010; 
Velikyan, et al., 2013), regardless of generator manufacturer. Consistent with the 
manufacturers’ generator specifications, 68Ge breakthrough was higher with the ITG 
generator (Table 1). 
 
The C18 solid-phase extraction procedure used in [68Ga]Ga-DOTA-NOC isolation 
provided a >100-fold reduction in the level of 68Ge breakthrough carried through to the 
final product.  For 44 doses produced using the EZAG generators we directly measured 
68Ge breakthrough in a residual sample of the fraction of generator eluate used in 
[68Ga]Ga-DOTA-NOC synthesis, as well as in the final [68Ga]Ga-DOTA-NOC product. 
68Ge breakthrough in the fractionated generator elute averaged 8.6 x 10-5 ± 1.3 x 10-4% 
(median 4.2 x 10-5%), but dropped to 3.0 x 10-7 ± 3.6 x 10-7% (median 1.9 x 10-7%) in the 
subsequent [68Ga]Ga-DOTA-NOC final product. Note, all breakthrough values were 
calculated for the time of [68Ga]Ga-DOTA-NOC dose expiration, not the time of 
generator elution, since the objective was to characterize product quality. Generator 
elution occurred, on average, 84-minutes and 86-minutes prior to the labeled dose 
expiration time using the EZAG and ITG generators, respectively (median values 83 
minutes and 85 minutes). 
 
Total synthesis time, from initiation of generator elution to post-QC release of final 
product, averaged 47 ± 5 minutes. Endotoxin testing was the rate-limiting QC test in 
progression to final dose release. The overall process required slightly more time when 
the ITG Fluidic Module was employed for solution transfers during tracer synthesis 
(Table 1), although the difference is judged to be inconsequential.  
 
Clinical whole-body (head to mid-thigh) PET/CT imaging with [68Ga]Ga-DOTA-NOC has 
consistently delivered high quality PET images that are fully consistent with prior 
literature reports on [68Ga]Ga-DOTA-NOC in evaluation of patients with neuroendocrine 
cancer  (Figures 4 and 5). The primary motivation for pursuing clinical [68Ga]Ga-DOTA-
NOC imaging via an Expanded Access IND was a critical local need for the best 
available approach to defining the extent of disease in patients with advanced 
neuroendocrine cancer who were being considered for multi-visceral organ 
transplantation (Mangus, et al., 2013). PET/CT with [68Ga]Ga-DOTA-NOC has also be 
quite useful in clinical evaluation of patients with either suspected neuroendocrine 
cancer, or a suspected neuroendocrine cancer recurrence, with the PET procedure often 
locating disease in patients for whom conventional 111In-Octreoscan imaging and 
conventional radiographs were  negative, but inconsistent with clinical presentation 
(Figure 5).   
 
CONCLUSIONS 
 
The manual [68Ga]Ga-DOTA-NOC synthesis methods, whether implemented with the 
EZAG or ITG generators, have been convenient, reliable and robust in 
radiopharmaceutical production for clinical use. With reasonable measures to minimize 
introduction of unnecessary trace metals (use of ultrapure reagents, an effort to minimize 
reagent volumes, and fractionated elution of the generator), we consistently obtained 
high purity [68Ga]Ga-DOTA-NOC while reliably remaining below the 50-µg limit for 
acceptable peptide mass (Virgolini, et al., 2010), even using the EZAG generator without 
pre-synthesis purification of the 68Ga3+. The Expanded Access IND has provided a 
valuable regulatory pathway for supplying this investigational drug, allowing [68Ga]Ga-
DOTA-NOC PET/CT to fulfill a critical need in the clinical care of patients with 
neuroendocrine cancer. 
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Figure 1.  Eppendorf Thermomixer fitted with the heating element for a 15-mm 
centrifuge tube. In our initial manual synthesis method, a single-use sterile 
centrifuge tube containing the [68Ga]Ga-DOTA-NOC reaction solution was simply 
heated in the 80°C thermomixer with swirling at ≥300 rpm for 10-minutes to 
complete the labeling reaction (with the apparatus shielded within >5-cm walls of 
lead bricks). 
 
 
Figure 2.  Disposable syringe and vial assembly used (with shielding, inside a laminar 
flow hood) for final [68Ga]Ga-DOTA-NOC product sterilization, and dispensing  of the 
patient dose.  The 25-gauge needle (blue hub) with attached 0.2-µm filter is used to vent 
the headspace during dose withdrawal. 
 
 
Figure 3.  Thin layer chromatography results for the [68Ga]Ga-DOTA-NOC product on 
ITLC-SG strips developed with 0.1M HCl or 1:1 methanol:1M aqueous NH4OAc, and 
corresponding behavior of the potential impurity of [68Ga]Ga-acetate (buffered reaction 
solution lacking DOTA-NOC). For each chromatogram, the dotted red line on the left 
side is the position of the origin, while the dotted line on the right is the position of the 
solvent front. 
 
 
 
Figure 4.  Sample whole-body [68Ga]Ga-DOTA-NOC PET images obtained for two 
patients at approximately 60-minutes post-injection (Siemens mCT camera). In both 
cases the patient dose of 68Ga was 170 MBq (4.6 mCi) and the DOTA-NOC dose 46-µg. 
The images of the patient on the left show extensive [68Ga]Ga-DOTA-NOC uptake in 
previously unknown metastatic lesions throughout the body. Images from the patient on 
the right also show multiple sites of metastatic disease, but these are confined to the 
liver and abdominal cavity. Following evaluation with [68Ga]Ga-DOTA-NOC PET, only 
the patient on the right remained a candidate for treatment by multi-visceral transplant. 
 
 
Figure 5.  Images of a carcinoid tumor patient obtained with both [68Ga]Ga-DOTA-NOC 
(196 MBq, 34-µg DOTA-NOC; imaged at 60-minutes post-injection) and 111In-
Octreoscan (231 MBq; imaged at 4-hours post-injection), the only FDA-approved agent 
for somatostatin-receptor-targeted neuroendocrine tumor imaging. In contrast to the 111In 
image, which appears normal, the 68Ga image reveals multiple metastatic lesions in the 
liver. (The pituitary also expresses somatostatin receptors and is visualized in the 68Ga 
PET image, along with normal uptake in the spleen, kidneys, and bladder.) The 68Ga 
PET scan was performed 2-weeks after the 111In scan because the patient’s symptoms 
were inconsistent with the 111In-Octreoscan findings. 
 
 Table 1. [68Ga]Ga-DOTA-NOC Dose Characteristics 
Parameter 
EZAG 
Generator 
ITG 
Generator 
Aggregate 
Data 
Number of Patients 47 127 174 
Administered Dose (mCi) 4.5 ± 0.7 
(median 4.6) 
5.0 ± 0.5 
(median 5.2) 
4.9 ± 0.6 
(median 5.1) 
Administered DOTA-NOC Dose (µg)* 43.2 ± 5.2 
(median 46) 
23.9  ± 5.7 
(median 23.5) 
29.1 ± 10.2 
(median 25.1)
Radiochemical Purity (%) 98.9 ± 0.4 
(median 98.8)
99.4 ± 0.3 
(median 99.5) 
99.2 ± 0.4 
(median 9.4) 
68Ge Breakthrough at Dose Expiration 
Time (%) 
2.8 x 10-7  
± 3.5 x 10-7 
(median 1.8 x 
10-7) 
5.4 x 10-5  
± 7.4 x 10-5 
(median 1.9 x 
10-5) 
4.0 x 10-5  
± 6.8 x 10-5 
(median 1.5 x 
10-5) 
Synthesis Time, Initiation of Elution to 
Post-QC Dose Release (minutes) 
46 ± 5  
(median 44) 
47 ± 4  
(median 46) 
47 ± 5 
(median 46) 
Elapsed Time, Initiation of Elution to Dose 
Expiration (minutes) 
84 ± 5 
(median 83) 
86 ± 6 
(median 85) 
85 ± 6 
(median 85) 
 
*Maximum possible value, assuming the total DOTA-NOC mass employed in the 
synthesis remains present in the final product solution (i.e., assuming no mass loss in 
material transfers or in the purification of product by C18 solid-phase extraction). 
